Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock


Rapamycin Restores Different Patterns of Cytokine Expression to Dexamethasone Treatment on CD14++CD16+ Monocytes from Steroid-Resistant Asthma Patients.


OBJECTIVE: We aimed to investigate the differences in interleukin (IL)-10, IL-1beta, IL-6, and tumor necrosis factor (TNF)-alpha expression in lipopolysaccharide (LPS)-stimulated CD14++CD16+ monocytes obtained from asthmatics after dexamethasone or dexamethasone plus rapamycin treatments between clinical steroid responders (R) and non-responders (NR). METHODS: Cytokine expressions in LPS-stimulated CD14++CD16+ p-mammalian target of rapamycin (mTOR) monocytes from R and NR were determined using flow cytometry. RESULTS: IL-10high CD14++CD16+ p-mTOR population following LPS stimulation increased in the R group although decreased in the NR group with dexamethasone treatment. IL-1betahigh population decreased in the R group although increased in the NR group. Rapamycin treatment after LPS and dexamethasone resulted in a significant increase in the IL-10high population and a significant decrease in the IL-1betahigh population in the NR group. CONCLUSION: Dexamethasone treatment resulted in different patterns of change in cytokine expressions in LPS-stimulated CD14++CD16+ p-mTOR monocytes between the R and NR. mTOR inhibition can restore steroid responsiveness involving IL-10 and IL-1beta in CD14++CD16+ p-mTOR monocytes.

Authors: Lee HS, Park HW, Lee SY,
Journal: Biol Pharm Bull;2023; 46 (4) 542. doi:10.1248/bpb.b22-00480
Year: 2023
PubMed: PMID: 37005298 (Go to PubMed)